Experience and impact of crystal pyrophosphate deposition (CPPD) from a patient and caregiver perspective: A qualitative exploration from the OMERACT CPPD working group

Fuller, Amy; Cai, Ken; Filippou, Georgios; Pascart, Tristan; Díaz-Torné, Cèsar; Hensey, Owen; Grossberg, David; Christensen, Robin; Shea, Beverley; Singh, Jasvinder A; Tedeschi, Sara K.; Dalbeth, Nicola; Abhishek, Abhishek

doi:10.1016/j.semarthrit.2021.04.010

Cited by 9 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, in a clinical subset, the use of pseudo-forms can confound patients, potentially leading to the mistaken belief that they are dealing with gout, rheumatoid arthritis or osteoarthritis instead of CPPD, relegating their disease to a secondary position compared to other conditions [5].…”

Section: Calcium Pyrophosphate Deposition's New Clothesmentioning

confidence: 99%

Describing calcium pyrophosphate deposition: undoing the tower of Babel!

Sirotti,

Terkeltaub,

Filippou

2024

Current Opinion in Rheumatology

Self Cite

View full text Add to dashboard Cite

Purpose of review In 1977, McCarty astutely observed, ‘The variety of names suggested for the condition associated with deposits of calcium pyrophosphate dihydrate crystals is exceeded only by the variations of its clinical presentation’. Fast forward to 2024, a standardized nomenclature for calcium pyrophosphate deposition (CPPD) is still lacking. This review aims to delineate the challenges in characterizing CPPD through nomenclature and imaging. Recent findings Despite the effort of nomenclature standardization in 2011 by the EULAR, confusion persists in the literature and clinical practice, with pseudo-forms and obscure abbreviations. The Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) has launched a project to redefine CPPD nomenclature and formulate a user-friendly language for effective communication with patients and other stakeholders. Additionally, recent advancements in imaging, have shed light on various aspects of the disorder. Summary Almost 60 years from the first description of a clinical manifestation related to calcium pyrophosphate crystals, a common language describing the disorder is still lacking. A redefined CPPD nomenclature, together with lay-friendly terminology, would significantly contribute to the uniformity of CPPD research, enhance public understanding and awareness and improve doctor-patient communication and therefore disease outcomes. Imaging can provide deep insights into CPPD elements, promoting comprehension of this disorder.

show abstract

Section: Calcium Pyrophosphate Deposition's New Clothesmentioning

confidence: 99%

Describing calcium pyrophosphate deposition: undoing the tower of Babel!

Sirotti,

Terkeltaub,

Filippou

2024

Current Opinion in Rheumatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Calcium Pyrophosphate Deposition (CPPD) Disease occurs when calcium pyrophosphate dihydrate (CPP) crystals are deposited in the articular cartilage and periarticular tissues. This condition is of concern in rheumatology because of its potential impact on a patient’s quality of life ( 1 ). CPPD disease is a clinically heterogeneous condition that can present in several forms, including acute calcium pyrophosphate (CPP) crystal arthritis, osteoarthritis (OA) with CPPD disease, chronic CPP crystal inflammatory arthritis, and crowned dens syndrome.…”

Section: Introductionmentioning

confidence: 99%

Calcium pyrophosphate deposition disease: historical overview and potential gaps

Pineda,

Sandoval,

Pérez-Neri

et al. 2024

Front. Med.

View full text Add to dashboard Cite

CPPD disease can affect patients’ quality of life through its various clinical presentations. This mini-review discusses the evolution of CPPD from its discovery to current knowledge of its pathogenesis, genetic associations, diagnostics, and treatment options. Despite extensive research, the exact mechanisms of CPPD are not well understood, and there is a notable lack of knowledge about psychosocial impacts and patient experiences. This study aims to present a CPPD Disease Timeline identifying gaps in current knowledge and potential directions for future research. These findings contribute to a broader understanding of CPPD disease and emphasize the importance of continued research and innovation in this field.

show abstract

“…Gout and calcium pyrophosphate (CPP) deposition disease are probably the two most common causes of acute crystal‐associated arthritis in humans. Both diseases are characterized by recurrent episodes of acute painful arthritis that can affect the patients' quality of life 1–3 . The primary aim of treating acute crystal‐associated arthritis is controlling pain and inflammation as soon as possible.…”

Section: Introductionmentioning

confidence: 99%

“…Both diseases are characterized by recurrent episodes of acute painful arthritis that can affect the patients' quality of life. [1][2][3] The primary aim of treating acute crystal-associated arthritis is controlling pain and inflammation as soon as possible.…”

Section: Introductionmentioning

confidence: 99%

Non‐loading versus loading low‐dose colchicine in acute crystal‐associated arthritis: A double‐blinded randomized controlled study

Laosuksri,

Phrintrakul,

Gumtorntip

et al. 2023

Int J of Rheum Dis

View full text Add to dashboard Cite

IntroductionThis study aimed to compare the efficacy of non‐loading versus loading low‐dose colchicine in patients with acute crystal‐associated arthritis.Materials and MethodsAll in‐patients who were admitted to Chiang Mai University Hospital with non‐arthritis disease and developed acute crystal‐associated arthritis during admission (within 48 h after arthritis onset) were invited to join this study. The patients were randomized into two groups. Patients in Group I (non‐loading group) and Group II (loading group) received colchicine at 1.2 and 2.4 mg in the first 24 h, respectively. The primary outcome was the patients' pain response at 24 h after treatment.ResultsOf 80 patients, 49 were acute gouty arthritis, and 31 acute calcium pyrophosphate (CPP) arthritis. The mean [95% CI] pain score was no different between Groups I and II at the baseline level (6.46[5.72–7.19] vs. 6.654[5.85–7.44], p = .867) and at 24 h (3.13[2.43–3.82] vs. 3.18[2.42–3.93], p = .907). The proportion of patients with ≥50% pain reduction was not different (57.50% vs. 55.00%, p = .822). Sensitivity analysis among patients with a baseline pain score of ≥4 showed the same pattern of response. Mild diarrhea was common and comparable in both groups. Subgroup analysis according to renal function (eGFR < 60 vs. ≥60 mL/min/1.73 m2) or type of crystals (acute gouty arthritis vs. acute CPP arthritis) also showed the same pattern of response.ConclusionNon‐loading low‐dose colchicine was as effective as loading low‐dose colchicine in patients with acute crystal‐associated arthritis, regardless of renal function or type of crystals.

show abstract

Experience and impact of crystal pyrophosphate deposition (CPPD) from a patient and caregiver perspective: A qualitative exploration from the OMERACT CPPD working group

Cited by 9 publications

References 20 publications

Describing calcium pyrophosphate deposition: undoing the tower of Babel!

Describing calcium pyrophosphate deposition: undoing the tower of Babel!

Calcium pyrophosphate deposition disease: historical overview and potential gaps

Non‐loading versus loading low‐dose colchicine in acute crystal‐associated arthritis: A double‐blinded randomized controlled study

Contact Info

Product

Resources

About